Log In
Print
BCIQ
Print
Print this Print this
 

subcutaneous beloranib (CKD-732, ZGN-440)

  Manage Alerts
Collapse Summary General Information
Company Chong Kun Dang Pharmaceutical Corp.
DescriptionSubcutaneous formulation of a methionine aminopeptidase 2 (MetAP2) inhibitor
Molecular Target Methionine aminopeptidase 2 (MetAP2)
Mechanism of ActionMethionine aminopeptidase 2 (MetAP2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationObesity
Indication DetailsTreat hypothalamic injury-associated obesity; Treat obesity; Treat obesity in patients with Prader-Willi syndrome
Regulatory Designation

U.S. - Orphan Drug (Treat obesity in patients with Prader-Willi syndrome);
EU - Orphan Drug (Treat obesity in patients with Prader-Willi syndrome)

Partner

Zafgen Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today